Company intelligence / Profile preview

StemCyte International

Baldwin Park, California, United States

Ownership: Private
Employees: ~131
Development stage: Other

Overview

StemCyte’s REGENECYTE, an allogeneic umbilical cord blood cell therapy, is the first such product globally to receive US FDA BLA approval (2024). The company has treated over 2,300 transplant patients with cord blood cell therapy and is conducting Phase II trials for long COVID and acute stroke, Phase I for cerebral palsy and other indications[1][2][5].

Therapeutic areas: OncologyHematologyInfectious DiseasesNeurology
Modalities: Cell therapyStem cell therapyUmbilical cord blood therapy
Industry: Biotech

Partnerships

City of HopeTaipei Medical University HospitalTzu Chi HospitalCalifornia State Umbilical Cord Blood Collection Program (CA-UCBCP)UC DavisApollo Hospital Group (India)Cadila Pharmaceutical (India)National Marrow Donor ProgramSharp Healthcare

Beyond the preview

Go deeper on StemCyte International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemCyte International.

Explore the full profile